Hino Utaro, Tamura Ryota, Kosugi Kenzo, Ezaki Taketo, Karatsu Kosuke, Yamamoto Kosei, Tomioka Azuna, Toda Masahiro
Department of Neurosurgery, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.
Department of Pharmacy, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.
Mol Clin Oncol. 2024 Apr 30;20(6):42. doi: 10.3892/mco.2024.2740. eCollection 2024 Jun.
Perampanel (PER) is an antiseizure medication (ASM) with a unique mechanism of action, which was approved in Japan for use in combination therapy in 2016 and as a monotherapy in 2020. It has exerted antitumor effects against several types of tumors . However, the efficacy of PER monotherapy for seizure control is not well-established in patients with brain tumor. In the present study, 25 patients with brain tumor treated using PER monotherapy at our institution were analyzed and compared with 45 patients treated using the most commonly prescribed ASM, levetiracetam (LEV). The PER group was younger and had a higher frequency of glioma cases. During drug administration, seizures were observed in two patients from the PER group (8.0%) and five patients from the LEV group (11.1%); however, the difference was not significant. The incidence of adverse effects did not significantly differ between the groups (12.0 and 2.2%, respectively). In the PER group, mild liver dysfunction was observed in two patients and drug rash in one. In the LEV group, a drug-induced rash was observed in one patient. PER monotherapy may be safe and effective for seizure treatment or prophylaxis in patients with brain tumor. Further large-scale clinical studies are warranted.
吡仑帕奈（PER）是一种具有独特作用机制的抗癫痫药物（ASM），于2016年在日本获批用于联合治疗，并于2020年获批用于单药治疗。它已对多种类型的肿瘤发挥了抗肿瘤作用。然而，PER单药治疗对脑肿瘤患者控制癫痫发作的疗效尚未得到充分证实。在本研究中，对我院使用PER单药治疗的25例脑肿瘤患者进行了分析，并与45例使用最常用的抗癫痫药物左乙拉西坦（LEV）治疗的患者进行了比较。PER组患者年龄较轻，胶质瘤病例频率较高。在给药期间，PER组有2例患者（8.0%）出现癫痫发作，LEV组有5例患者（11.1%）出现癫痫发作；然而，差异不显著。两组不良反应的发生率无显著差异（分别为12.0%和2.2%）。在PER组中，2例患者出现轻度肝功能障碍，1例出现药疹。在LEV组中，1例患者出现药物性皮疹。PER单药治疗对脑肿瘤患者的癫痫治疗或预防可能是安全有效的。有必要进行进一步的大规模临床研究。
